(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 43.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Nuvation Bio's revenue in 2026 is $143,046,000.On average, 13 Wall Street analysts forecast NUVB's revenue for 2026 to be $72,085,762,874, with the lowest NUVB revenue forecast at $62,143,982,759, and the highest NUVB revenue forecast at $79,090,754,412. On average, 12 Wall Street analysts forecast NUVB's revenue for 2027 to be $103,161,246,273, with the lowest NUVB revenue forecast at $74,844,458,444, and the highest NUVB revenue forecast at $131,230,100,702.
In 2028, NUVB is forecast to generate $149,353,682,997 in revenue, with the lowest revenue forecast at $87,188,748,119 and the highest revenue forecast at $267,977,592,545.